1.130USDMkt Cap: 4.30M USDP/E: —Last update: 2026-05-22
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a the…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap4.30M USD
Enterprise Value1.74M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.51M USD
Revenue/Share—
Last Price1.130 USD
Fiscal Year EndApr 2025
MR QuarterJan 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.45
PEG—
EV/EBITDA-0.25
EV/Revenue—
P/S—
P/B2.04
EPS (TTM)-3.67
EPS (Forward)-2.60
52W Range
1.11318% of range1.210
52W High1.210 USD
52W Low1.113 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-113.78%
ROA-98.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.57M USD
CapEx (TTM)300.00K USD
FCF Margin—
FCF Yield-84.10%
Net Debt-2.71M USD
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity—
Current Ratio1.99
Quick Ratio1.46
Book Value/Sh0.5740 USD
Cash/Share0.7130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:9
Split DateMay 12, 2025
Analyst Consensus
Rating—
Target (Mean)25.00 USD
Target Range25.00 USD – 25.00 USD
# Analysts1
Ownership
Shares Out.3.80M
Float3.79M
Insiders0.53%
Institutions3.04%
Short Interest
Short Ratio2.4d
Short % Float5.41%
Short % Out.5.38%
Shares Short204.74K
Short (prev mo.)326.19K
Technical
SMA 501.233 (-8.4%)
SMA 2001.989 (-43.2%)
Beta0.11
S&P 52W Chg28.31%
Avg Vol (30d)59.20K
Avg Vol (10d)78.57K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—